公开(公告)号：WO2009140320A1

公开(公告)日：2009-11-19

申请号：PCT/US2009/043691

申请日：2009-05-13

Applicant: ARRAY BIOPHARMA INC. ,  LE HUEROU, Yvan ,  BLAKE, James, F. ,  GUNWARDANA, Indrani, W. ,  MOHR, Pete ,  WALLACE, Eli, M. ,  WANG, Bin ,  CHICARELLI, Mark ,  LYON, Michael

Inventor： LE HUEROU, Yvan ,  BLAKE, James, F. ,  GUNWARDANA, Indrani, W. ,  MOHR, Pete ,  WALLACE, Eli, M. ,  WANG, Bin ,  CHICARELLI, Mark ,  LYON, Michael

IPC: C07D471/04 ,  A61K31/437 ,  A61P35/00

CPC classification number: C07D471/04 ,  C07D401/06 ,  C07D519/00

Abstract: Compounds of Formula (I) are useful for inhibition of CHKl and/or CHK2. Methods of using compounds of Formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Abstract translation: 式（I）的化合物可用于抑制CHK1和/或CHK2。 公开了使用式（I）化合物及其立体异构体及其药学上可接受的盐在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

公开(公告)号：WO2012154274A1

公开(公告)日：2012-11-15

申请号：PCT/US2012/026572

申请日：2012-02-24

Applicant: ARRAY BIOPHARMA INC. ,  BLAKE, James, F ,  DELISLE, Robert, Kirk ,  DE MEESE, Lisa, A. ,  GRAHAM, James, M. ,  LE HUEROU, Yvan ,  LYON, Michael ,  ROBINSON, John, E. ,  WALLACE, Eli, M. ,  WANG, Bin ,  XU, Rui

Inventor： BLAKE, James, F ,  DELISLE, Robert, Kirk ,  DE MEESE, Lisa, A. ,  GRAHAM, James, M. ,  LE HUEROU, Yvan ,  LYON, Michael ,  ROBINSON, John, E. ,  WALLACE, Eli, M. ,  WANG, Bin ,  XU, Rui

IPC: C07D401/06 ,  C07D471/04 ,  C07D519/00 ,  A61K31/4709 ,  A61P29/00

CPC classification number: C07D471/04 ,  C07D401/06 ,  C07D487/04 ,  C07D487/10 ,  C07D491/048 ,  C07D519/00

Abstract: Compounds of Formula I: in which R 1 , R 2 , R 3 , R 4 and R 10 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by PIM-1 and/or PIM-2 and/or PIM-3 kinases.

Abstract translation: R 1，R 2，R 3，R 4和R 10具有本说明书中给出的含义的式I化合物是可用于治疗由PIM-1和/或PIM-2和/或PIM-2介导的疾病的受体酪氨酸抑制剂， 3激酶。

公开(公告)号：WO2007015824A3

公开(公告)日：2007-02-08

申请号：PCT/US2006/027738

申请日：2006-07-17

Applicant: INTERMUNE, INC. ,  ARRAY BIOPHARMA INC. ,  SEIWERT, Scott D. ,  BLATT, Lawrence M. ,  ANDREWS, Steven W. ,  MARTIN, Pierre ,  SCHUMACHER, Andreas ,  BARNETT, Bradley, R. ,  EARY, Todd, C. ,  KAUS, Robert ,  KERCHER, Timothy ,  LIU, Weidong ,  LYON, Michael ,  NICHOLS, Paul ,  WANG, Bin ,  SAMMAKIA, Tarek ,  KENNEDY, April ,  JIANG, Yutong

Inventor： SEIWERT, Scott D. ,  BLATT, Lawrence M. ,  ANDREWS, Steven W. ,  MARTIN, Pierre ,  SCHUMACHER, Andreas ,  BARNETT, Bradley, R. ,  EARY, Todd, C. ,  KAUS, Robert ,  KERCHER, Timothy ,  LIU, Weidong ,  LYON, Michael ,  NICHOLS, Paul ,  WANG, Bin ,  SAMMAKIA, Tarek ,  KENNEDY, April ,  JIANG, Yutong

IPC: C07K5/12 ,  A61K38/00 ,  A61P31/14 ,  C07D209/44 ,  C07C231/02 ,  C07C269/00 ,  C07D207/16

Abstract: The embodiments provide compounds of the general Formulae (I) through general Formula (VIII), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

公开(公告)号：WO2009089359A1

公开(公告)日：2009-07-16

申请号：PCT/US2009/030450

申请日：2009-01-08

Applicant: ARRAY BIOPHARMA INC. ,  BLAKE, James ,  GUNAWARDANA, Indrani W. ,  LE HUEROU, Yvan ,  MOHR, Peter J. ,  WALLACE, Eli M. ,  WANG, Bin

Inventor： BLAKE, James ,  GUNAWARDANA, Indrani W. ,  LE HUEROU, Yvan ,  MOHR, Peter J. ,  WALLACE, Eli M. ,  WANG, Bin

IPC: C07D471/04 ,  A61K31/4162 ,  A61P35/00

CPC classification number: C07D471/04

Abstract: Compounds of Formula I are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Abstract translation: 式I的化合物可用于抑制CHK1和/或CHK2。 公开了使用式I化合物及其立体异构体及其药学上可接受的盐在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

公开(公告)号：WO2009089352A1

公开(公告)日：2009-07-16

申请号：PCT/US2009/030443

申请日：2009-01-08

Applicant: ARRAY BIOPHARMA INC. ,  BLAKE, James ,  GUNAWARDANA, Indrani W. ,  LE HUEROU, Yvan ,  MOHR, Peter J. ,  WALLACE, Eli M. ,  WANG, Bin

Inventor： BLAKE, James ,  GUNAWARDANA, Indrani W. ,  LE HUEROU, Yvan ,  MOHR, Peter J. ,  WALLACE, Eli M. ,  WANG, Bin

IPC: C07D471/04 ,  A61K31/496 ,  A61P35/00

CPC classification number: C07D471/04

Abstract: Compounds of Formula (I) are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ , and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Formula, (I).

Abstract translation: 式（I）的化合物可用于抑制CHK1和/或CHK2。 公开了使用式（I）化合物及其立体异构体及其药学上可接受的盐在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。 ）。

公开(公告)号：WO2005051304A3

公开(公告)日：2005-06-09

申请号：PCT/US2004/039094

申请日：2004-11-19

Applicant: ARRAY BIOPHARMA INC. ,  MITCHELL, Ian, S. ,  SPENCER, Keith, L. ,  STENGEL, Peter ,  HAN, Yongxin ,  KALLAN, Nicholas, C. ,  MUNSON, Mark ,  VIGERS, Guy, P., A. ,  BLAKE, James ,  PISCOPIO, Anthony ,  JOSEY, John ,  MILLER, Scott ,  XIAO, Dengming ,  XU, Riu ,  RAO, Chang ,  WANG, Bin ,  BERNACKI, April, L.

Inventor： MITCHELL, Ian, S. ,  SPENCER, Keith, L. ,  STENGEL, Peter ,  HAN, Yongxin ,  KALLAN, Nicholas, C. ,  MUNSON, Mark ,  VIGERS, Guy, P., A. ,  BLAKE, James ,  PISCOPIO, Anthony ,  JOSEY, John ,  MILLER, Scott ,  XIAO, Dengming ,  XU, Riu ,  RAO, Chang ,  WANG, Bin ,  BERNACKI, April, L.

IPC: A61K31/53 ,  A61K31/519 ,  A61K31/496 ,  C07D257/12 ,  C07D253/00 ,  C07D401/00

Abstract: The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula: A-L-CR where CR is a cyclical core group, L is a linking group and A is as defined herein. Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.

公开(公告)号：WO2008137779A2

公开(公告)日：2008-11-13

申请号：PCT/US2008/062552

申请日：2008-05-02

Applicant: INTERMUNE, INC. ,  ARRAY BIOPHARMA, INC. ,  BLATT, Lawrence, M. ,  PAN, Lin ,  SEIWERT, Scott ,  ANDREWS, Steven, W. ,  MARTIN, Pierre ,  SCHUMACHER, Andreas ,  BEIGELMAN, Leonid ,  LIU, Jyanwei ,  CONDROSKI, Kevin ,  JIANG, Yutong ,  KAUS, Robert ,  KENNEDY, April ,  KERCHER, Timothy ,  LYON, Michael ,  WANG, Bin

Inventor： BLATT, Lawrence, M. ,  PAN, Lin ,  SEIWERT, Scott ,  ANDREWS, Steven, W. ,  MARTIN, Pierre ,  SCHUMACHER, Andreas ,  BEIGELMAN, Leonid ,  LIU, Jyanwei ,  CONDROSKI, Kevin ,  JIANG, Yutong ,  KAUS, Robert ,  KENNEDY, April ,  KERCHER, Timothy ,  LYON, Michael ,  WANG, Bin

IPC: C07D487/04 ,  C08H1/00 ,  A61K31/407 ,  A61P31/12

CPC classification number: C07D487/04

Abstract: The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Abstract translation: 实施方案提供了通式I的化合物，以及包含主题化合物的组合物，包括药物组合物。 实施方案还提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。

公开(公告)号：EP2990407A1

公开(公告)日：2016-03-02

申请号：EP15175131.0

申请日：2009-05-13

Applicant: Array Biopharma, Inc.

Inventor： LE HUEROU, Yvan ,  BLAKE, James, F. ,  GUNWARDANA, Indrani, W. ,  MOHR, Peter, J. ,  WALLACE, Eli, M. ,  WANG, Bin ,  CHICARELLI, Mark ,  LYON, Michael

IPC: C07D471/04 ,  A61K31/437 ,  A61P35/00

Abstract: Compounds of Formula I are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

Abstract translation: 式I化合物可用于抑制CHK1和/或CHK2。 公开了使用式I化合物及其立体异构体及其药学上可接受的盐在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

公开(公告)号：EP2242757B1

公开(公告)日：2012-08-01

申请号：EP09701216.5

申请日：2009-01-08

Applicant: Array Biopharma, Inc.

Inventor： BLAKE, James ,  GUNAWARDANA, Indrani W. ,  LE HUEROU, Yvan ,  MOHR, Peter J. ,  WALLACE, Eli M. ,  WANG, Bin

IPC: C07D471/04 ,  A61K31/4162 ,  A61P35/00

CPC classification number: C07D471/04

Abstract: Compounds of Formula I are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

公开(公告)号：EP2242755A1

公开(公告)日：2010-10-27

申请号：EP09700828.8

申请日：2009-01-08

Applicant: Array Biopharma, Inc.

Inventor： BLAKE, James ,  GUNAWARDANA, Indrani W. ,  LE HUEROU, Yvan ,  MOHR, Peter J. ,  WALLACE, Eli M. ,  WANG, Bin

IPC: C07D471/04 ,  A61K31/496 ,  A61P35/00

CPC classification number: C07D471/04

Abstract: Compounds of Formula (I) are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula (I) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.Formula, (I).